JP2005528430A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005528430A5 JP2005528430A5 JP2004508790A JP2004508790A JP2005528430A5 JP 2005528430 A5 JP2005528430 A5 JP 2005528430A5 JP 2004508790 A JP2004508790 A JP 2004508790A JP 2004508790 A JP2004508790 A JP 2004508790A JP 2005528430 A5 JP2005528430 A5 JP 2005528430A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- levodopa
- carbidopa
- pharmaceutical dosage
- release component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002552 dosage form Substances 0.000 claims 48
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 28
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 28
- 229960004502 levodopa Drugs 0.000 claims 28
- 238000013270 controlled release Methods 0.000 claims 18
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 18
- 229960004205 carbidopa Drugs 0.000 claims 17
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 17
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 claims 9
- 238000000338 in vitro Methods 0.000 claims 7
- 239000002245 particle Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 239000012062 aqueous buffer Substances 0.000 claims 5
- 238000004090 dissolution Methods 0.000 claims 4
- 238000001727 in vivo Methods 0.000 claims 3
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 239000007909 solid dosage form Substances 0.000 claims 2
- 229940123736 Decarboxylase inhibitor Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 239000003954 decarboxylase inhibitor Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229960003638 dopamine Drugs 0.000 claims 1
- NULMGOSOSZBEQL-QMMMGPOBSA-N etilevodopa Chemical compound CCOC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 NULMGOSOSZBEQL-QMMMGPOBSA-N 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/158,412 US20030224045A1 (en) | 2002-05-29 | 2002-05-29 | Combination immediate release sustained release levodopa/carbidopa dosage forms |
| US10/241,837 US7094427B2 (en) | 2002-05-29 | 2002-09-12 | Combination immediate release controlled release levodopa/carbidopa dosage forms |
| PCT/US2003/016391 WO2003101432A1 (en) | 2002-05-29 | 2003-05-23 | Combination immediate release controlled release levodopa/carbidopa dosage forms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005528430A JP2005528430A (ja) | 2005-09-22 |
| JP2005528430A5 true JP2005528430A5 (enExample) | 2010-01-21 |
Family
ID=29582673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004508790A Pending JP2005528430A (ja) | 2002-05-29 | 2003-05-23 | 組合せ即時放出および制御放出レボドーパ／カルビドーパ剤型 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20030224045A1 (enExample) |
| EP (1) | EP1507518B1 (enExample) |
| JP (1) | JP2005528430A (enExample) |
| AU (1) | AU2003247409B2 (enExample) |
| CA (1) | CA2486859C (enExample) |
| IL (1) | IL164856A (enExample) |
| WO (1) | WO2003101432A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040052843A1 (en) * | 2001-12-24 | 2004-03-18 | Lerner E. Itzhak | Controlled release dosage forms |
| US20040166159A1 (en) * | 2002-05-29 | 2004-08-26 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa |
| US7094427B2 (en) * | 2002-05-29 | 2006-08-22 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
| US20060013875A1 (en) * | 2002-05-29 | 2006-01-19 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
| ITMI20030827A1 (it) * | 2003-04-18 | 2004-10-19 | Unihart Corp | Composizione farmaceutica contenente l'associazione levodopa/carbidopa. |
| US8007827B2 (en) | 2004-04-02 | 2011-08-30 | Impax Laboratories, Inc. | Pharmaceutical dosage forms having immediate release and/or controlled release properties |
| WO2006035414A2 (en) * | 2004-09-30 | 2006-04-06 | Ranbaxy Laboratories Limited | Carbidopa and levodopa dispersible tablets |
| US20070003621A1 (en) * | 2005-06-23 | 2007-01-04 | Spherics, Inc. | Dosage forms for movement disorder treatment |
| AR055106A1 (es) * | 2005-08-05 | 2007-08-08 | Osmotica Pharmaceutical Argent | Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa |
| WO2007073702A2 (es) | 2005-12-29 | 2007-07-05 | Osmotica Corp. | Comprimido multicapa con combinación de triple liberación |
| US20080131492A1 (en) * | 2006-06-23 | 2008-06-05 | Spherics, Inc. | Dosage forms for movement disorder treatment |
| PE20080669A1 (es) * | 2006-09-08 | 2008-07-18 | Drugtech Corp | Composicion de liberacion sostenida que comprende levodopa |
| US20100316712A1 (en) * | 2006-12-22 | 2010-12-16 | Combinatorx, Incorporated | Pharmaceutical compositions for treatment of parkinson's disease and related disorders |
| KR101752080B1 (ko) * | 2007-12-28 | 2017-06-28 | 임팩스 라보라토리즈, 인코포레이티드 | 레보도파 방출 제어형 제제 및 이의 용도 |
| WO2010019915A1 (en) | 2008-08-15 | 2010-02-18 | Depomed Inc. | Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders |
| EP2508174A1 (en) | 2011-04-06 | 2012-10-10 | Ljiljana Sovic Brkicic | Pharmaceutical composition |
| US10987313B2 (en) | 2013-10-07 | 2021-04-27 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
| ES2823000T3 (es) | 2013-10-07 | 2021-05-05 | Impax Laboratories Llc | Formulaciones muco-adhesivas de liberación controlada de levodopa y/o ésteres de levodopa y usos de las mismas |
| WO2018011181A1 (en) * | 2016-07-11 | 2018-01-18 | Contera Pharma Aps | Pulsatile drug delivery system for treating morning akinesia |
| US11986449B2 (en) | 2020-12-22 | 2024-05-21 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
| JP2024501235A (ja) | 2020-12-22 | 2024-01-11 | アムニール ファーマスーティカルズ エルエルシー | レボドパ投薬レジメン |
| WO2024024865A1 (ja) * | 2022-07-28 | 2024-02-01 | 大原薬品工業株式会社 | レボドパ持続性製剤 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2513940A1 (de) * | 1975-03-29 | 1976-10-14 | Merck Patent Gmbh | Pharmazeutische zubereitung |
| US4077407A (en) * | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
| US4424235A (en) * | 1981-09-14 | 1984-01-03 | Hoffmann-La Roche Inc. | Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor |
| US5188840A (en) * | 1985-09-26 | 1993-02-23 | Chugai Seiyaku Kabushiki Kaisha | Slow-release pharmaceutical agent |
| IT1188212B (it) * | 1985-12-20 | 1988-01-07 | Paolo Colombo | Sistema per il rilascio a velocita' controllata di sostanze attive |
| ZA889189B (en) * | 1986-06-16 | 1989-08-30 | Merck & Co Inc | Controlled release combination of carbidopa/levodopa |
| IT1255522B (it) * | 1992-09-24 | 1995-11-09 | Ubaldo Conte | Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita' |
| GB9309749D0 (en) * | 1993-05-12 | 1993-06-23 | Boots Co Plc | Therapeutic agents |
| IT1282576B1 (it) * | 1996-02-06 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili |
| US6756056B2 (en) * | 1997-04-08 | 2004-06-29 | Alan A. Rubin | Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa |
| IT1295271B1 (it) * | 1997-10-03 | 1999-05-04 | Chiesi Farma Spa | Monolita contenente uno o piu'farmaci costituito da tre strati a meccanismo di rilascio differenziato |
| WO2000015197A1 (en) * | 1998-09-14 | 2000-03-23 | Rubin Alan A | Improvement in treatment of parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa |
| FI109453B (fi) * | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| JP2004501190A (ja) * | 2000-06-23 | 2004-01-15 | テバ ファーマシューティカル インダストリーズ リミティド | 治療薬の胃部保留および制御された放出のための急速膨張する組成物とその組成物を含む剤形 |
| IL159813A0 (en) * | 2001-07-12 | 2004-06-20 | Teva Pharma | Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core |
-
2002
- 2002-05-29 US US10/158,412 patent/US20030224045A1/en not_active Abandoned
-
2003
- 2003-05-23 CA CA002486859A patent/CA2486859C/en not_active Expired - Fee Related
- 2003-05-23 WO PCT/US2003/016391 patent/WO2003101432A1/en not_active Ceased
- 2003-05-23 EP EP03756204.8A patent/EP1507518B1/en not_active Expired - Lifetime
- 2003-05-23 AU AU2003247409A patent/AU2003247409B2/en not_active Ceased
- 2003-05-23 JP JP2004508790A patent/JP2005528430A/ja active Pending
-
2004
- 2004-10-27 IL IL164856A patent/IL164856A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005528430A5 (enExample) | ||
| ES2606463T3 (es) | Combinación de formas de dosificación de levodopa/carbidopa de liberación inmediata y liberación controlada | |
| JP5749255B2 (ja) | Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復 | |
| JP7534354B2 (ja) | 朝の無動状態を治療するための拍動性薬物送達系 | |
| CA2601289A1 (en) | Once-a-day oxycodone formulations | |
| RU2011110765A (ru) | Фармацевтическая композиция энтакапона или его солей пролонгрированного высвобождения | |
| ES2212667T3 (es) | Formulacion de liberacion controlada con divalproex sodico. | |
| CA2486859A1 (en) | Combination immediate release controlled release levodopa/carbidopa dosage forms | |
| EP2105133A1 (en) | Intragastric floating-type levodopa sustained-release preparation | |
| JP2008520736A5 (enExample) | ||
| KR20160135373A (ko) | 주의력 결핍 장애의 치료를 위한 방법 및 조성물 | |
| JPS63139128A (ja) | Ｌ―ドーパ含有組成物 | |
| MD3684344T2 (ro) | Comprimate de deferipronă cu eliberare întârziată și metode de utilizare a acestora | |
| EP3013327B1 (en) | Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin | |
| RU2004109920A (ru) | Фармацевтическая композиция, включающая лумиракоксиб | |
| RU2003100507A (ru) | Фармацевтические композиции | |
| JP2007509146A5 (enExample) | ||
| JP2005519052A5 (enExample) | ||
| CN104379138B (zh) | 阿坎酸制剂、其使用方法及包含阿坎酸制剂的组合 | |
| RU2261098C2 (ru) | Перорально распадающаяся композиция, содержащая миртазапин | |
| US20060159751A1 (en) | Controlled release pharmaceutical compositions of carbidopa and levodopa | |
| JP2020531543A5 (enExample) | ||
| TW200800155A (en) | Gastric retentive gabapentin dosage forms and methods for using same | |
| US20180368458A1 (en) | Time release vitamins and minerals in edible oils | |
| JP2016539171A (ja) | アセブロフィリン及び疎水性徐放性基剤を含む徐放性薬学組成物 |